At a glance
ClinicalIndex Comparison RecordN/ACompleted· 191 enrolled
Drug / intervention
Palbociclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Cohort Study of Patients With Hormone Receptor-positive Metastatic Breast Cancer Treated With Palbociclib (Ibrance(Registered)) as Part of the United Kingdom Ibrance (Registered) Patient Program (IPP); the Real Outcomes Ibrance (Registered) Study (ROIS)
In Brief
An observational study evaluating Palbociclib for HR+/HER2- Locally Advanced, Metastatic Breast Cancer. Completed, enrolled 191 participants across 8 sites.
Detailed Summary
What are the real-world treatment patterns, patients' characteristics, clinical outcomes and healthcare resource utilisation associated with palbociclib treatment in the 3 years following initiation in United Kingdom patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer treated as part of the IPP?
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2019
First PostedApr 2019
Primary CompletionMar 2021
TodayJul 2026
First PostedApr 19, 2019
Enrollment StartMar 1, 2019
Primary CompletionMar 4, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.2 years ago
Interventions
Palbociclibdrug
Palbociclib